TerminatedPhase 2NCT02958917
Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis
Studying Fibrotic hypersensitivity pneumonitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Evans Fernandez Perez
- Principal Investigator
- Evans Fernández, MD, MSNational Jewish Health
- Intervention
- Pirfenidone(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2017 – 2021
Study locations (1)
- National Jewish Health, Denver, Colorado, United States
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02958917 on ClinicalTrials.gov